GRPR versus PSMA: expression profiles during prostate cancer progression demonstrate the added value of GRPR-targeting theranostic approaches.

ABSTRACT:

Introduction

Central to targeted radionuclide imaging and therapy of prostate cancer (PCa) are prostate-specific membrane antigen (PSMA)-targeting radiopharmaceuticals. Gastrin-releasing peptide receptor (GRPR) targeting has been proposed as a potential additional approach for PCa theranostics. The aim of this study was to investigate to what extent and at what stage of the disease GRPR-targeting applications can complement PSMA-targeting theranostics in the management of PCa.

Methods

Binding of the GRPR- and PSMA-targeting radiopharmaceuticals [¹⁷⁷Lu]Lu-NeoB and [¹⁷⁷Lu]Lu-PSMA-617, respectively, was evaluated and compared on tissue sections of 20 benign prostatic hyperplasia (BPH), 16 primary PCa and 17 progressive castration-resistant PCa (CRPC) fresh

SUBMITTER: Verhoeven M 

PROVIDER: S-EPMC10502172 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature